PPT-Warfarin Therapy

Author : ellena-manuel | Published Date : 2016-09-18

Nicolas Novitzky The Ideal Oral Anticoagulant Ideally an oral anticoagulant would Have high efficacy in reducing thromboembolic events Reach therapeutic levels

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Warfarin Therapy" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Warfarin Therapy: Transcript

Nicolas Novitzky The Ideal Oral Anticoagulant Ideally an oral anticoagulant would Have high efficacy in reducing thromboembolic events Reach therapeutic levels within several hours Oral. coumadin toxicity signs and symptoms xanax. coumadin benadryl interaction. drug interactions coumadin and viagra venlafaxine coumadin. buy coumadin testing self. coumadin machine for sale prick. coumadin diet information in vitamin k foods high. Eliot Williams, MD PhD. Division of Hematology & Medical Oncology. Nothing to disclose. History of anticoagulant therapy. 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010. Allyson Sarigianis, Pharm.D.. October 19, 2013. Objectives. Review current practice recommendations for prevention of stroke/systemic embolism in atrial fibrillation. Compare and contrast pharmacology between warfarin and target specific oral anticoagulants (TSOACs). (. N. OAC). Dan . Moellentin. , . PharmD. , BCPS, Associate Professor . Husson. University. Strokes in Atrial Fibrillation. 1/5 of strokes are caused by a. fib. 1/3 cardiac arrhythmias hospitalizations . versus Warfarin Therapy for Prevention of Stroke . in Patients with Atrial Fibrillation: A Randomized . Non-Inferiority Trial. David R. Holmes, MD. Vivek Y. Reddy, MD. Zoltan G. Turi, MD. Shephal K. Doshi, MD. st. century: A practical guide to using newer Agents. Katherine Vogel Anderson, . Pharm.D. ., BCACP. University of Florida Colleges of Pharmacy and Medicine. Disclosures . I have nothing to disclose. Dabigatran . Etexilate versus Warfarin in Patients Undergoing . Catheter . Ablation of Atrial Fibrillation: . The RE-CIRCUIT™ . Study. Hugh Calkins, . M.D.,. 1. Stephan . Willems. , M.D., Atul . Verma. Meta-Analysis and Implications . David R. Holmes, Jr., M.D.. Mayo Clinic, Rochester . TCT 2014. Washington, D.C.. September 2014. Presenter Disclosure Information. David R. Holmes, Jr., M.D.. “. Watchman II: PROTECT AF/PREVAIL. CHEST Guidelines 2016. Jennifer . Mah. , MD. March 2016. Case. A 44-year-old man is evaluated in follow-up for an episode of unprovoked left proximal leg deep venous thrombosis 3 months ago. Following initial anticoagulation with low-molecular-weight heparin, he began treatment with . Mary N. Healy, MS, ARNP-BC. Heart & Vascular Center of Sarasota. OBJECTIVES. Define the difference between paroxysmal and persistent Atrial Fibrillation. State the CVA risk per year of a 68 . yr. Advantages of NOACs. No INR monitoring required. No bridging required . Easier to manage around surgical procedures. Convenient for rural patients or those with other barriers to . clinic . visits. Fewer. www.onlinecjc.com. ). . . If your reuse request qualifies as medical institution internal education, you may reuse the material under the following conditions:. You must cite the Canadian Journal of Cardiology and the Canadian Cardiovascular Society as references.. 1 COUMADIN Tablets for oralLactose, starch and magnesium stearate 1 mg: D&C Red No. 6 Barium Lake 2 mg: FD&C Blue No. 2 Aluminum Lake and FD&C Red No. 40 Aluminum Lake 2-1/2 mg: D&C Yellow No. 10 Therapy Training. 03/10/2015. Objectives. 1. What is an . anticoagulant. . ?. 2. Why is anticoagulant therapy necessary?. 3. What is a PT/INR?. 4. Who can give Warfarin sodium?. Heart. Pumps blood through the body.

Download Document

Here is the link to download the presentation.
"Warfarin Therapy"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.